Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10
Evercore Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $7
Evercore ISI Remains a Buy on Savara (SVRA)
Savara Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Savara Analyst Ratings
JMP Securities Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9
Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $15
JMP Securities Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9
Buy Rating Affirmed for Savara on Strong Prospects for Molgramostim in APAP Treatment
Evercore Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $7
Savara (SVRA) Receives a Buy From Evercore ISI
Savara Analyst Ratings
JMP Securities Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9
Buy Rating for Savara Affirmed on Positive Phase 3 Trial Results and Strong Market Potential
Savara Analyst Ratings
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10
Evercore Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $7